

## Special Issue

# Advances in Cancer Immunotherapy and Vaccines Research

### Message from the Guest Editor

A tumor vaccine is an active method to specifically increase antitumor immune cells. In addition to CD8 T-cells, which play an essential role in tumor vaccination by directly killing tumor cells, innumerable reports have indicated that CD4 T-cells also have a direct cytotoxic activity against tumors. The main aim of this Special Issue is to gather the latest advances in the field of tumor immunology to optimize a tumor vaccine. Potential topics for this Special Issue include, but are not limited to, the following: - Immune adjuvants for a tumor vaccine; - Immunological assessment of the tumor microenvironment; - Combination of immunotherapy and chemoradiotherapy; - Optimization of administration route and/or formula in a tumor vaccine; - Immune cell polarization and immunotherapy; - Impeding immune suppression in the tumor microenvironment; - Re-education of immune cells in the tumor microenvironment;

### Guest Editor

Dr. Takumi Kumai

Department of Otolaryngology Head and Neck Surgery, Asahikawa Medical University, Midorigaoka East 2-1-1, Asahikawa, Hokkaido 0788510, Japan

### Deadline for manuscript submissions

closed (31 January 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/123135](https://mdpi.com/si/123135)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).